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KAJIAN FARMAKOGENETIK TENTANG PERSEPSI KESAKITAN AKUT DI 
KALANGAN PESAKIT YANG DIRAWAT DENGAN TERAPI GANTIAN 
METADON (MMT) 
 
ABSTRAK 
 
OPRM1 dan ABCB1 terlibat dalam modulasi kesakitan dan kesan terhadap rawatan 
analgesik. Polimorfisme gen OPRM1 dan ABCB1 merupakan antara sebab terdapatnya 
perbezaan dalam respons terhadap ujikaji kesakitan di antara individu. Objektif kajian 
ini adalah untuk mengkaji pengaruh faktor farmakogenetik terhadap kesakitan ke atas 
pesakit terapi gantian metadon (MMT) dan individu yang opioid naif. Protokol kajian 
telah mendapat kelulusan Jawatankuasa Etika Penyelidikan Manusia, USM, Kelantan 
dan Jawatankuasa Etika & Penyelidikan Perubatan, Kementerian Kesihatan Malaysia, 
Malaysia. Kajian berbentuk keratan rentas ini bermula Mac hingga Oktober 2013 dan 
melibatkan 148 orang pesakit penagih dadah yang menerima rawatan metadon dari 
klinik MMT di Kelantan dan juga 152 orang lelaki Melayu sihat yang opioid naif. 
Individu yang mempunyai keputusan ujian air kencing yang positif dadah, mengalami 
kesakitan kronik dan akut, dan mengalami keadaan lain yang boleh mempengaruhi 
kesakitan atau keputusan ujian perendaman tangan dalam air sejuk (CPT) tidak dipilih 
untuk kajian. Penerangan yang lengkap tentang kajian diberikan terlebih dahulu kepada 
subjek sebelum mendapatkan persetujuan mereka secara bertulis. Respons terhadap 
kesakitan kesejukan termasuk tahap permulaan kesakitan (pain threshold), toleransi 
kesakitan (pain tolerance) dan intensiti kesakitan (pain intensity) diukur menggunakan 
CPT. DNA diekstrak daripada darah dan digunakan untuk mengesan genotip OPRM1 
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dan ABCB1. Kajian ini mendapati bahawa pesakit yang menerima MMT adalah lebih 
sensitif kepada kesakitan (hyperalgesia) seperti yang ditunjukkan oleh tahap permulaan 
kesakitan dan toleransi kesakitan yang lebih cepat. Di kalangan individu yang opioid 
naif, terdapat kaitan yang signifikan antara polimorfisme 2677G>T/A dengan tahap 
permulaan kesakitan dan toleransi kesakitan. Selain itu, individu yang mempunyai alel 
3435T (genotip 3435 CT dan TT) menunjukkan intensiti kesakitan yang lebih tinggi 
berbanding individu yang mempunyai genotip 3435 CC. Diplotip 1236 CC/2677 GG/ 
3435 CC didapati mempunyai kaitan yang signifikan dengan tahap permulaan kesakitan 
dan toleransi kesakitan yang lebih tinggi. Individu yang mempunyai diplotip 1236 
TT/2677 TT/ 3435 TT menunjukkan intensiti kesakitan yang lebih tinggi berbanding 
individu tanpa diplotip ini. Walaubagaimanapun, polimorfisme OPRM1 didapati tidak 
mempunyai kaitan yang signifikan dengan respons terhadap CPT. Di kalangan pesakit, 
genotip IVS2+691 CC didapati mempunyai kaitan yang signifikan dengan toleransi 
kesakitan yang lebih rendah, tetapi diplotip AC/AG bagi polimorfisme OPRM1 didapati 
mempunyai kaitan yang signifikan dengan toleransi kesakitan yang lebih tinggi. Alel 
2677G didapati mempunyai kaitan yang signifikan dengan tahap permulaan kesakitan 
dan toleransi kesakitan yang lebih rendah, dan alel 2677G atau haplotip CGC bagi 
polimorfisme ABCB1 didapati mempunyai kaitan yang signifikan dengan toleransi 
kesakitan yang lebih tinggi. Diplotip CGC/TTT didapati mempunyai kaitan yang 
signifikan dengan kepekatan metadon yang lebih tinggi. Keputusan kajian ini boleh 
menjadi asas bagi pemahaman berkaitan pengaruh faktor genetik kepada respons 
terhadap ujikaji kesakitan di kalangan pesakit yang dirawat dengan MMT dan individu 
yang opioid naif. Polimorfisme ABCB1 boleh menjadi faktor peramal kepada kesan 
terhadap rawatan metadon.  
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A PHARMACOGENETICS STUDY ON ACUTE PAIN PERCEPTION AMONG 
PATIENTS ON METHADONE MAINTENANCE THERAPY (MMT) 
 
ABSTRACT 
 
OPRM1 and ABCB1 are involved in pain modulation and analgesic responses. It is 
possible that OPRM1 and ABCB1 polymorphisms contribute to inter-individual 
differences in experimental pain responses. The objectives of this study were to 
investigate the pharmacogenetic factors that influence pain responses in patients on 
methadone maintenance therapy (MMT) and opioid-naive individuals. The protocol for 
the study was approved by the Human Research Ethics Committee (HREC), USM in 
Kelantan, and the Medical Research & Ethics Committee (MREC), at the MOH, 
Malaysia. This cross-sectional study involved Malay males opioid-dependent patients 
receiving MMT from MMT clinics in Kelantan (n = 148) and healthy opioid-naive 
individuals from the local population (n = 152), recruited from March to October, 2013. 
Excluded were individuals with a positive result of urine screening for drug test, chronic 
or ongoing acute pain, and other conditions that may affect pain or cold pressor test 
(CPT). Written informed consent was obtained from the subjects after full explanation of 
the study procedure. Cold pain responses including pain threshold, pain tolerance, and 
pain intensity were measured using the CPT. DNA was extracted from whole blood and 
genotyped for OPRM1 and ABCB1 polymorphisms. This study revealed hyperalgesia 
among opioid-dependent patients, as manifested by their quicker detection of pain and 
quicker hand withdrawal. In healthy opioid-naive individuals, the 2677G>T/A 
polymorphism of ABCB1 was associated with pain threshold and pain tolerance. In 
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addition, carriers of 3435T allele (3435 CT and TT genotypes) exhibited significantly 
higher pain intensity scores than carriers of the 3435 CC genotype. The 1236 CC/2677 
GG/ 3435 CC diplotype was associated with a higher cold pain threshold and also pain 
tolerance. Individuals with 1236 TT/2677 TT/ 3435 TT diplotype exhibited higher pain 
intensity scores compared to those without this diplotype. However, OPRM1 
polymorphisms were not associated with cold pain responses in opioid-naive 
individuals. In the opioid-dependent patients, the IVS2+691 CC genotype was 
associated with a lower pain tolerance, but AC/AG diplotype of 118A>G and 
IVS2+691G>C polymorphisms of OPRM1 were associated with a higher pain tolerance. 
The  2677G allele for 2677G>T/A polymorphism was associated with lower pain 
threshold and pain tolerance, and 2677G allele or CGC haplotype for the 1236C>T, 
2677G>T/A, and 3435C>T polymorphisms of ABCB1 were associated with a higher 
pain intensity scores. The CGC/TTT diplotypes was associated with a higher serum 
methadone concentration. These findings may become the foundation for understanding 
of genetic contributions to experimental pain responses in opioid-dependent patients on 
MMT and opioid-naive individuals. ABCB1 polymorphisms may be a predictor for the 
treatment outcomes of opioid-dependent patients on MMT. 
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CHAPTER 1 
INTRODUCTION AND REVIEW OF LITERATURE 
 
1.1 Methadone Maintenance Therapy (MMT) and Pain Complaint  
 
Methadone is well known and effective in the treatment of opioid dependence. 
Maintenance pharmacological treatments are effective in retaining patients in treatment 
and suppressing drug use (Amato et al., 2011). Research evaluating the healthcare costs 
associated with treatment of opioid dependence with medications found that patients 
who received medication had lower hospital utilization and total costs than patients who 
did not receive pharmacologic therapy (Baser et al., 2011). Many patients with opioid 
dependence are now receiving methadone maintenance therapy (MMT) in Malaysia.  
Drug use is common in Malaysia (Chemi et al., 2014). Among patients on MMT in 
Malaysia, the starting age for drug use was between 14 to 35 years and the mean age at 
enrolment into MMT was 42 years (Manan et al., 2013). This is a productive and active 
age group. It is therefore likely that clinicians will more frequently encounter patients on 
MMT for management of pain due to trauma, acute medical illness and chronic diseases, 
and surgery (Eyler, 2013). Opioid maintenance therapy may however alter sensitivity to 
pain (Compton et al., 2000; Compton et al., 2001; Doverty et al., 2001a; Doverty et al., 
2001b; Athanasos et al., 2006; Hay et al., 2009; Compton et al., 2012; Krishnan et al., 
2012). Unfortunately, clinicians often underestimate the pain complaints in this patient 
population (Alford et al., 2006; Eyler, 2013).  
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Patients on MMT therefore often receive undertreatment for pain. There is a lack 
of awareness among physician about treatment of chronic and acute pain in this patient 
population. For instance, patients receive inadequate doses of opioid analgesic for their 
pain (Scimeca et al., 2000; Alford et al., 2006; Hines et al., 2008; Eyler, 2013). On the 
other hand, poor pain management may be a risk factor for relapse for individuals with 
addiction in remission (Tsui et al., 2010; Chang and Compton, 2013), and may 
contribute to discontinuation of MMT.  The consequent continued use of illicit opiates 
poses challenges in the treatment of patients with opiate dependence (Eyler, 2013). 
 
In addition to medical provider barriers, patient factors may also contribute to 
poor pain management in opioid dependence. Opioid-dependent patients frequently 
report increased pain sensitivity (Compton et al., 2000; Compton et al., 2001; Doverty et 
al., 2001a; Doverty et al., 2001b; Athanasos et al., 2006; Pud et al., 2006; Hay et al., 
2009; Compton et al., 2012; Krishnan et al., 2012). Cross-tolerance to opioids may also 
be present (Doverty et al., 2001a; Athanasos et al., 2006), and they may need more 
analgesia. Indeed, evidence has shown that opioid-dependent patients require higher 
than normal doses of opioid analgesics. Despite significantly greater plasma morphine 
concentrations, methadone patients experienced minimal anti-nociception in comparison 
with controls (Doverty et al., 2001a). Higher morphine doses may achieve some pain 
relief, but this may be at the cost of unacceptable respiratory depression (Athanasos et 
al., 2006). It is thus important for clinicians to understand pain sensitivity among 
patients on MMT for more effective pain management. 
 
3 
 
The present study investigated pain sensitivity using cold pressor test (CPT) 
among and between opioid-naive subjects and opioid-dependent patients on MMT, 
against a hypothesis that there are significant differences in pain sensitivity within 
groups, and between this patient population and the general population.  
 
1.2 Hyperalgesia in Opioid-Dependent Patients on Methadone Maintenance 
Therapy (MMT) 
 
Several studies on pain sensitivity among opioid-dependent patients on MMT 
have been undertaken previously in several populations in California, USA (Compton et 
al., 2000; Compton et al., 2001; Compton et al., 2008; Compton et al., 2010; Compton 
et al., 2012), in Israel (Pud et al., 2006; Peles et al., 2011), and in Australia (Doverty et 
al., 2001a; Doverty et al., 2001b; Athanasos et al., 2006; Hay et al., 2009; Krishnan et 
al., 2012). Studies found that heightened pain sensitivity was frequently reported in 
opioid-dependent patients on MMT. They also found that their opioid-dependent 
patients on MMT were more pain sensitive compared to controls.  
 
Pain is however complex. Environments, both internal and external may play a 
role in both pain experience and pain control. Malaysia is a multi-ethnic country. 
Previous studies have indicated that there occurred large inter-ethnic and intra-ethnic 
pharmacologic differences among the Malaysian population. Pain sensitivity data are 
largely unavailable in Malaysia. Experimental pain studies may provide important 
information regarding pain sensitivity in these patients. This study sought to fill this gap.  
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1.3 Mu-Type Opioid Receptor Gene (OPRM1) 
 
Several studies in Malaysia have suggested that pharmacogenetics variability 
may be an important factor in pharmacologic variability in the Malaysian population 
(Zahari et al., 2009; Haerian et al., 2011; Zahari et al., 2011; Teh et al., 2012; Zahari 
and Ismail, 2014; Wei et al., 2015). The genetically polymorphic mu-type opioid 
receptor (MOR-1) or μ-opioid receptor (hMOP) is one of the major types of opioid 
receptors (Chen et al., 1993). Others include kappa (κ-opioid receptor) and delta-type 
opioid receptors (δ-opioid receptor). These receptors are also known as MOR, KOR, and 
DOR; or more recently OP3, OP2, and OP1
Chen et al., 
1993
, respectively. All the three major types of 
opioid receptors belong to the G protein-coupled receptor superfamily (
; Min et al., 1994; Mansour et al., 1995; Bond et al., 1998; Burford et al., 2000). It 
is located on presynaptic or postsynaptic neurons depending upon cell types (Olive et 
al., 1997; Pennock and Hentges, 2011). It is mainly expressed in the central nervous 
system (CNS) including the brainstem (periaqueductal gray, PAG), thalamus, 
 
cortex, 
and spinal cord (Mansour et al., 1995). It is also expressed in peripheral tissues such as 
in intestinal tract (Bagnol et al., 1997) and immune cells (Mousa et al., 2001). 
It has been suggested that the efficacy of most of the commonly used opioids is 
associated with its affinity for μ-opioid receptor. The μ-opioid receptor-binding efficacy 
of morphine and related opioid analgesics is highly correlated with their ability to 
modulate pain. Genetic factors that affect the density and function, consequently the 
signaling efficacy of μ-opioid receptor, may contribute to inter-individual variations in 
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the response to opioids (Befort et al., 2001; Klepstad et al., 2004; Ravindranathan et al., 
2009). 
 
The μ-opioid receptor gene (OPRM1) is mapped to chromosome 6q24−q25 
(Wang et al., 1994) (Figure 1.1). The OPRM1 has 400 amino acids, 236 371 bp’s and 
has molecular weight of 44 779 Da and four coding exons that are separated by three 
introns
 
 (GenBank accession number NC_000006). 
Receptor cloning has identified more than 17 isoforms (splice variants) of human 
μ-opioid receptor such as isoform 2 (MOR1A or MOR-1A) (Bare et al., 1994), isoform 
5 (MOR-1C or MOR-1O), and isoform 3 (MOR-1R or MOR-1X) (Pan et al., 2003).  
The difference between these variants is in the tip of the intracellular C-terminus, far 
from the binding pocket of the receptor protein (Choi et al., 2006; Pasternak, 2010).    
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Figure 1.1 Mu-Type Opioid Receptor Gene (OPRM1) Structure and Polymorphisms Studied. 
 
Boxes represent exons; horizontal lines connecting boxes represent introns, promoter and untranslated regions; arrows indicate relative 
locations of the polymorphisms. This figure is build based on UCSC Genome Browser on Human Feb. 2009 (GRCh37/hg19) Assembly 
which is available at http://genome.ucsc.edu. 
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1.4 OPRM1 Polymorphisms 
 
At present, more than 2757 polymorphisms of OPRM1 have been identified 
(http://www.ncbi.nlm.nih.gov/projects/SNP/ and http://www.genecards.org) including 
118A>G (dbSNP rs1799971), IVS2+31G>A (dbSNP rs9479757), and IVS2+691G>C 
(dbSNP rs2075572)  (Smolka et al., 1999; Hoehe et al., 2000; Shi et al., 2002; Klepstad 
et al., 2004; Lotsch and Geisslinger, 2006; Olsen et al., 2012).  
 
In a study by Bond et al. (1998), they detected five variants, all single nucleotide 
polymorphisms (SNPs) in the μ-opioid receptor  including A118G, G24A, G779A, and 
G942A  among 113 former heroin addicts on methadone maintenance and 39 individuals 
with no history of drug or alcohol abuse or dependence. The most prevalent SNP was 
the A118G (also known as 118A>G, dbSNP rs1799971 and Asn40Asp) that cause an 
amino acid exchange in the receptor protein. In exon 1, a substitution of aspartate (D) for 
asparagine (N) was found at codon 40, Asn40Asp, which corresponds to the N-terminal 
region of the receptor in the extracellular space. It is predicted to result in the removal of 
a putative N-glycosylation site and therefore might be expected to affect the μ-opioid 
receptor N-glycosylation and reduced stability of the receptor in cell cultures (Huang et 
al., 2012). N-glycosylation plays a part in many cellular processes like receptor folding, 
sorting, expression, and ligand binding.  
 
Bond et al. (1998) also found that the A118G variant receptor bind β-endorphin 
approximately three times stronger than the wild-type receptor. However, no differences 
in binding affinities for most opioid peptides and alkaloids tested were observed 
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suggesting that the A118G polymorphism did not change the overall binding properties 
of the receptor. The predicted amino acid change as a result of the A118G SNP is a 
single residue substitution in the N-terminal region in the extracellular space and is 
unlikely to drastically affect the overall tertiary structure of the receptor. At the 
molecular level, Zhang et al. (2005) found a 1.5 to 2.5-fold reduced mRNA expression 
of the μ-opioid receptor in human brain autopsy tissues of 118G carriers and a further 
10-fold reduction in protein levels has been found in cell cultures. 
 
The 118G allele has been found to be associated with reduced analgesic efficacy 
to opioids agents, higher opioid requirements or less pain relief  (Klepstad et al., 2004; 
Romberg et al., 2005; Chou et al., 2006a; Chou et al., 2006b; Oertel et al., 2006; Reyes-
Gibby et al., 2007; Campa et al., 2008; Hayashida et al., 2008; Sia et al., 2008; Fukuda 
et al., 2009; Ginosar et al., 2009; Tan et al., 2009; Wu et al., 2009; Zhang et al., 2010; 
Zwisler et al., 2010; Liu and Wang, 2012). The 118A>G polymorphism were also 
reported to be associated with specific phenotypes such as alcohol dependence (Town et 
al., 1999; Kim et al., 2004), opioid addiction (Szeto et al., 2001; Tan et al., 2003; 
Nagaya et al., 2012), substance dependence (Schinka et al., 2002), pain sensitivity 
(Fillingim et al., 2005; Oertel et al., 2006), and obsessive compulsive disorder (Urraca et 
al., 2004). Evidences are however inconsistent (Bergen et al., 1997; Sander et al., 1998; 
Gelernter et al., 1999; Hoehe et al., 2000; Li et al., 2000; Franke et al., 2001; Shi et al., 
2002; Crowley et al., 2003; Ross et al., 2005; Coulbault et al., 2006; Janicki et al., 2006; 
Huang et al., 2008; Landau et al., 2008; Lötsch et al., 2009; Wong et al., 2010; Klepstad 
et al., 2011; Camorcia et al., 2012). 
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Polymorphisms that do not cause amino acid exchanges but are frequent or have 
also been proposed to have functional consequences include IVS2+31G>A and 
IVS2+691G>C SNPs found in intron 2. Substitution of Adenine (A) for Guanine (G) at 
31 bp downstream of exon 2 (IVS2+31G>A) and substitution of Cytosine (C) for 
Guanine (G) at 691 bp downstream of exon 2 (IVS2+691G>C) located within intron 2 
(Hoehe et al., 2000; Xin and Wang, 2002; Lotsch and Geisslinger, 2006), may however 
change the affinity of the transcriptional regulatory factors for the intronic DNA 
sequence and directly alter mRNA levels, and therefore may change the regulation of the 
expression of OPRM1 gene. Additionally, intronic sequence can be involved in 
alternative DNA splicing, resulting in different isoforms of human μ-opioid receptor 
(Wendel and Hoehe, 1998; Hoehe et al., 2000). 
 
IVS2+31G>A polymorphism have been found to be associated with higher 
pressure pain threshold in healthy adult females resulting in lower pressure pain 
sensitivity than those without this SNP (Huang et al., 2008). However, IVS2+31G>A 
polymorphism showed no influence on the efficacy of morphine in cancer pain patients 
(Klepstad et al., 2004). The IVS2+31A carrier, especially subjects carrying both the 
IVS2+31G>A and the A118G polymorphisms also had higher level of addiction to 
heroin resulting in higher heroin intake dosages than non-carriers of those mutations 
(Shi et al., 2002). The mechanism for this is unknown.  
 
The IVS2+691G>C polymorphism however did not increase morphine 
requirements in patients with pain caused by malignant disease (Klepstad et al., 2004) 
and did not have significant association with 24-h post-operative opioid requirement 
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(Hayashida et al., 2008). Association between C1031G (IVS2+691G>C) polymorphism 
and heroin dependence was also reported in Chinese subjects Szeto et al., 2001 ( ) but Li 
et al. (2000) and Tan et al. (2003) failed to show an association between this 
polymorphism  and heroin abuse.  
Zhang et al., 2007
Self-reported positive responses on first use of heroin 
such as euphoria were also found not to be associated with this polymorphism or A118G 
polymorphism ( ). Furthermore, results from Bergen et al. (1997) 
 
did 
not support a role of this polymorphism in susceptibility to alcohol dependence.  
Details on characteristic and position of OPRM1 polymorphisms are shown in 
Table 1.1 and OPRM1 alleles frequencies in patients with pain are shown in Table 1.2. 
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Table 1.1 Characteristics and Positions of OPRM1 Polymorphisms  
Polymorphism  Characteristic mutation (s) Amino acid 
location  
Synonyms 
    
118A>G 
(dbSNP 
rs1799971) 
 
At nucleotide 118 in exon 1, 
an Adenine (A) is changed to 
a Guanine (G)  
 
 
 
N40D 
(Asn40Asp) 
OPRM1:c.118A>G 
SNP,  
dbSNP rs61596185,  
dbSNP rs17181017,  
dbSNP
g.154360797A>G, 
 rs52818856, 
g.154039662A>G, 
g.34162A>G, 
c.118A>G, 
c.397A>G, 
c.-11+28644A>G, 
c.47+29103A>G, 
p.Asn40Asp, 
p.Asn133Asp, 
A118G, 
304A/G, 
ASN40ASP,  
Asn40Asp,  
N40D, 
OPRM1 118 
 
IVS2+31G>A 
(dbSNP 
rs9479757) 
 
Guanine (G) to Adenine (A) 
substitution at 31 bp 
downstream of exon 2 
(Intron 2) 
- dbSNP rs60522300, 
dbSNP
g.154411344G>A, 
 rs17174808, 
g.154090209G>A, 
g.84709G>A, 
c.343+31G>A, 
c.400+31G>A, 
c.643+31G>A, 
c.922+31G>A,  
IVS2+G31A, 
IVS2 +31G→A, 
OPRM1 31, 
OPRM1 50665 
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Table 1.1 ……Continued 
Polymorphism  Characteristic mutation (s) Amino acid 
location  
Synonyms 
    
IVS2+691G>C 
(dbSNP 
rs2075572) 
 
Guanine (G) to Cytosine (C) 
substitution at nucleotide 
+691 in intron 2 
- dbSNP rs56680128, 
dbSNP rs17210094, 
dbSNP
g.154412004G>C,  
 rs17174815, 
g.154090869G>C, 
g.85369G>C, 
c.644-83G>C, 
c.923-83G>C, 
c.344-83G>C, 
c.401-83G>C, 
IVS2+G691C, 
C1031G, 
OPRM1 691, 
OPRM1 51325 
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Table 1.2 OPRM1 Alleles Frequencies in Patients with Pain 
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
118G allele    
Chronic cancer pain    
Klepstad et al. (2004) Caucasian 206 10.4 
Ross et al. (2005) Caucasian 156 15.1 
Campa et al. (2008) Italian Caucasian 138 15.2 
Liu and Wang (2012) Chinese 96 39.6 
Labor pain    
Landau et al. (2008) 1. Caucasian 213 17.8 
 2. Asian 10 40.0 
 3. All cases 223 18.8 
Camorcia et al.(2012) Italian Caucasian 77 16.2 
Wong et al. (2010) Mixed 
(White/Caucasian, 
African-American, 
Asian and Hispanic) 
190 15.3 
Post-operative pain    
Tan et al. (2009) 1. Chinese  620 33.9 
 2. Malays  241 49.0 
 3. Indian  137 44.1 
Zhang et al. (2010) Chinese  174 31.3 
Sia et al. (2008) Chinese Singaporean 585 33.6 
Wu et al. (2009) Han Chinese 189 30.2 
Hayashida et al. (2008) Japanese  138 44.9 
Fukuda et al. (2009) Japanese 280 43.8 
Chou et al.(2006a) Taiwanese 80 34.4 
Chou et al. (2006b) Taiwanese 120 24.6 
Tsai et al. (2010) 
 
Taiwanese 212 32.6 
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Table 1.2 ……Continued  
References  Ethnicity Number of subject, 
N 
Frequency 
(%) 
118G allele    
Post-operative pain    
Janicki et al. (2006) American  101 15.8 
Kolesnikov et al.(2011) Caucasian 102 11.3 
Coulbault et al. (2006) French Caucasian 74 12.8 
Bruehl et al.(2006) Mixed 
White Non-Hispanic, 
African-American 
and Other 
48 12.5 
Wong et al. (2010) Mixed 
(White/Caucasian, 
African-American, 
Asian and Hispanic) 
103 13.6 
Chronic pain    
Janicki et al. (2006) American 131 7.9 
Menon et al.(2012) Australian Caucasian 153 11.8 
Lötsch et al. (2009) 
 
Caucasian 352 14.4 
IVS2+31A allele    
Chronic cancer pain    
Klepstad et al. (2004) Caucasians  206 9.7 
Ross et al. (2005) 
 
Caucasians 156 8.7 
IVS2+691C allele    
Chronic cancer pain    
Klepstad et al. (2004) Caucasians  206 61.2 
Ross et al. (2005) Caucasians 156 55.1 
Post-operative pain    
Hayashida et al. (2008) 
 
Japanese  138 79.3 
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1.5 OPRM1 Polymorphisms and Pain Sensitivity 
 
Genetic and environmental factors interactions may further influence pain 
sensitivity (Young et al., 2012). Polymorphisms in genes involved in pain processing 
predict variation in pain sensitivity (Govoni et al., 2008; Lind and Gordh, 2009; Lotsch 
et al., 2009; Miaskowski, 2009; Kim and Schwartz, 2010; Kasai and Ikeda, 2011; 
Shipton, 2011). It is known that opioidergic mechanisms are involved in the responses to 
nociceptive stimuli (Holden et al., 2005; Sprenger et al., 2006; Eippert et al., 2009; 
Schoell et al., 2010). The mu-type opioid receptor (OPRM1) is the primary binding site 
for endogenous opioid peptides β-endorphin and endomorphin (Mizoguchi et al., 2000) 
and exogenous opioids, including methadone and morphine (Saidak et al., 2006). 
Studies showed that the activation of the OPRM1 system is associated with reductions in 
the sensory and affective ratings of the pain experience (Zubieta et al., 2001).  
 
Variability in the modulation of pain or pain sensitivity and large inter-individual 
differences in treatment outcomes with opioid analgesic therapy suggest varied 
sensitivity to endogenous and exogenous opioids, and potential variability in the 
OPRM1 receptor protein and gene (Govoni et al., 2008; Lind and Gordh, 2009; Lotsch 
et al., 2009; Miaskowski, 2009; Kim and Schwartz, 2010; Kasai and Ikeda, 2011; 
Shipton, 2011; Young et al., 2012). A previous study in healthy males has shown that 
striatal OPRM1 availability predicted the cold pressor pain threshold. They found that 
healthy males with low OPRM1 binding potential in the striatum are associated with a 
low cold pain threshold (Hagelberg et al., 2012). They hypothesised that individuals 
with low OPRM1 binding potential have low receptor density, and consequently, low 
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level of OPRM1-mediated suppression of pain pathways, leading to increased sensitivity 
to experimental pain (Hagelberg et al., 2012). 
 
Martin et al.(2003) observed that a low endogenous opioid tone in the regulation 
of physiological pain in opioid receptor knockout mice was associated with increased 
nociceptive responsiveness. The A118G polymorphism is a candidate mutation with 
potential importance for nociceptive responsiveness because it has been found to 
increase the receptor affinity of β-endorphin by a factor of three (Bond et al., 1998). 
This may be hypothesised to increase the activity in the endogenous opioid system. A 
high endogenous opioid tone in the regulation of physiological pain may be associated 
with a decreased response to nociceptive stimulation.  
 
Previous studies have also suggested an influence of polymorphisms of the 
OPRM1 gene (OPRM1) on pain phenotypes in healthy subjects (Fillingim et al., 2005; 
Lotsch et al., 2006; Huang et al., 2008). A genetic study indicated that 118A>G 
polymorphism of the OPRM1 gene also influenced experimental pain responses in 
healthy subjects (Fillingim et al., 2005; Lotsch et al., 2006). Individuals with 118G 
allele exhibited lower sensitivity to pressure pain (higher pressure pain thresholds) 
compared to those with wild-type allele (Fillingim et al., 2005). A relationship between 
118A>G polymorphism and heat pain perception has also been previously described in 
healthy individuals, and its direction was dependent on gender, where the 118G allele 
was associated with lower pain ratings among males but higher pain ratings among 
females (Fillingim et al., 2005). As the 118G allele has been found to increase the 
receptor affinity of β-endorphin (Bond et al., 1998), and consequently, increase the 
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activity in the endogenous opioid system, these findings supported the hypothesis that 
the 118A>G polymorphism of the OPRM1 gene was associated with increased 
endogenous opioid tone (Fillingim et al., 2005). 
 
The IVS2+31G>A polymorphism was also found to be associated with pressure 
pain sensitivity in healthy adult females. Pressure pain threshold in subjects with the 
major allele (termed ‘GG’) genotype was significantly lower than those with minor 
allele (termed ‘GA’) genotype (Huang et al., 2008). However, evidence of a possible 
role of IVS2+691G>C polymorphism in the risk of altered pain sensitivity among 
healthy individuals is limited.  
 
Table 1.3 summarises the association studies of OPRM1 polymorphisms with 
pain sensitivity. In total, the studies have raised a great number of questions over the 
potential role of the OPRM1 polymorphisms in pain sensitivity but with no clear 
resolution. Thus, the association between pain sensitivity and OPRM1 polymorphisms 
remains controversial. Further studies are necessary to evaluate the results of these 
association studies between OPRM1 polymorphisms and pain sensitivity. 
 
In addition to this lack of concordance in the literature, it is not known whether 
the inter-individual variations in pain responses are influenced by OPRM1 
polymorphisms in the healthy Malay male population.  This study was designed to 
clarify the position in the literature, and to determine whether healthy Malay male 
variations in cold pressor pain responses are influenced by OPRM1 polymorphisms. 
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Table 1.3  Association Studies of OPRM1 Polymorphisms with Pain Sensitivity 
References  Ethnicity Number of 
subject, N 
Frequency 
(%) 
Type of pain Result 
118G allele       
Fillingim et al.(2005) American 167 11.4 Thermal, mechanical, 
and ischemic pain  
G-allele carriers had lower 
pressure pain sensitivity (higher 
pressure pain thresholds) than AA 
subjects. 
No association with heat and 
ischemic pain sensitivity. 
Lötsch et al.(2006) White 45 10.0 Corticol responses to 
trigeminal pain 
stimuli 
G-allele carriers had lower 
sensitivity to nociceptive stimuli 
[lower N1 event-related potential 
(ERP) response to CO2
Zhang et al.(
] than AA 
subjects. 
2010) Chinese 174 31.3 Electrical stimulation 
pain 
G-allele carriers had higher 
electrical stimulation pain 
sensitivity (lower pain tolerance 
thresholds) than AA subjects. 
Huang et al.(2008) Taiwanese 72 31.9 Mechanical pain No association. 
Fukuda et al.(2009) Japanese 280 43.8 Cold pressor-induced 
pain 
No association. 
IVS2+31A allele      
Huang et al.(2008) Taiwanese 72 2.8 Mechanical pain GA genotype carriers had lower 
pressure pain sensitivity (higher 
pressure pain thresholds) than GG 
subjects. 
IVS2+691C allele      
Huang et al.(2008) Taiwanese 72 0.0 Mechanical pain Not analysed. 
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1.6 OPRM1 Polymorphisms and Inter-Individual Variations in the Response to 
Opioids 
 
The μ-opioid receptor (OPRM1) is a primary target for the clinically important 
opioid analgesics, including morphine, fentanyl, and methadone. It has been suggested 
that the efficacy and side-effects of most of the commonly used opioids is associated 
with its affinity for μ-opioid receptor. In fact, the μ-opioid receptor-binding efficacy of 
morphine and related opioid analgesics is highly correlated with their ability to modulate 
pain. Genetic factors that affect the density and function and consequently the signaling 
efficacy of μ-opioid receptor may contribute to inter-individual variations in the 
response to opioids (Befort et al., 2001; Klepstad et al., 2004; Ravindranathan et al., 
2009).  
 
In total, the studies have raised a great deal of speculation over the potential role 
of the OPRM1 polymorphisms in lowered pain sensitivity, increased opioid dose 
requirements, reduced opioid analgesia, and reduced risk of side-effects such as nausea, 
vomiting and pruritus but with no clear resolution (Zahari and Ismail, 2013). 
 
Opioid-dependent patients on MMT exhibit abnormal pain sensitivity called 
opioid-induced hyperalgesia (i.e. increased pain sensitivity after opioid administration). 
The finding of shorter pain tolerance times (withdrawal latencies) in response to pain 
tests among opioid maintained addicts compared to healthy controls has been shown 
consistently in many studies providing further evidence that opioid-dependent patients 
are more sensitive to painful stimuli than are others (Compton et al., 2000; Compton et 
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al., 2001; Pud et al., 2006; Hay et al., 2009; Krishnan et al., 2012). There is inter-
individual variation in opioid-induced hyperalgesia among methadone users and 
hyperalgesia may weaken their determination to abstain (Eyler, 2013). 
 
Several studies have also reported on the association between methadone 
treatment and OPRM1 polymorphisms (Compton et al., 2003; Bunten et al., 2010; 
Fonseca et al., 2010; Bunten et al., 2011; Wang et al., 2012). Although evidence shows 
that OPRM1 polymorphisms are associated with changes in libido and insomnia, and 
methadone-related deaths, the relationship of OPRM1 polymorphisms with abnormal 
pain sensitivity among opioid-dependent patients on methadone therapy is not fully 
understood. Thus far, one study explored the possibility that the OPRM1 polymorphisms 
could provide a possible explanation for the noted pain intolerance of opioid addicted 
individuals (Compton et al., 2003). Unfortunately, this showed that the role of the 
polymorphisms remains uncertain due to the low frequencies of the variants in the study 
samples.  
 
A better understanding of the role of OPRM1 polymorphisms in pain and opioid 
response has implications for the treatment of pain and addictive disease, and clinical 
management of each in the presence of the other. In the present study, we aimed to 
investigate the influence of OPRM1 polymorphisms on pain responses among opioid-
dependent patients on methadone therapy in Malay patients. 
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1.7 ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 1 gene 
(ABCB1)  
 
The ATP-Binding Cassette, Sub-Family B (MDR/TAP), Member 1 (ABCB1) 
gene [also known as multidrug resistance (MDR1) gene] encodes P-glycoprotein (P-gp), 
an efflux transporter that transports its substrates out of the cells (Kim, 2002). It is 
located on chromosomal region 7q21 (Fojo et al., 1986) (Figure 1.2). Its cDNA spans 
about 4.5 kb with 28 exons, encoding a 1280-amino acid (multidrug resistance protein 1) 
with the size 170 kDa (Chen et al., 1990). The P-gp is highly expressed in endothelial 
cells of the brain vasculature, and it is believed to affect the efflux of endogenous and 
exogenous substrates across the blood-brain barrier (BBB) (Schinkel et al., 1996; King 
et al., 2001; Kastin et al., 2002). This causes a lower concentration of substrates such as 
morphine in the cell, and reduces the effectiveness of the substrates (Hamabe et al., 
2007).  
 
The function of P-gp may be affected by ABCB1 polymorphisms, with certain 
polymorphisms leading to decreased mRNA, and P-gp expression and activity (Hitzl et 
al., 2001; Kim et al., 2001; Sauer et al., 2002; Meissner et al., 2004; Leschziner et al., 
2007). However, the associations between ABCB1 polymorphisms and ABCB1 mRNA 
and protein expression, and function of P-gp have been inconclusive (Leschziner et al., 
2007).  
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Figure 1.2 ABCB1 Protein and Gene Structure Showing the Polymorphisms 
Studied.  
A. Gene structure of ABCB1 on human chromosome 7q21.12 and polymorphisms studied. Boxes 
in the ABCB1 gene structure represent exons; horizontal lines connecting boxes represent 
introns, promoter and untranslated regions; arrows indicate relative locations of the 
polymorphisms. This figure is build based on the AceView genes as of January 2016 which is 
available at http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly. B. ABCB1 protein and known 
polymorphisms as reported by Meletiadis et al. (2006). The studied polymorphisms are 
highlighted in boxes.  
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1.8 ABCB1 Polymorphisms 
 
The most common polymorphisms found in ABCB1 include 1236C>T (dbSNP 
rs1128503), 2677G>T/A (dbSNP rs2032582), and 3435C>T (dbSNP rs1045642). The 
silent 3435C>T polymorphism in exon 26 of ABCB1 involves a transition of cytosine 
(C) to thymine (T) at nucleotide 3435. This synonymous polymorphism is found at 
residue 1145 in the second ATP binding domain, which is located at a cytoplasmic loop 
of P-gp. It does not result in an amino acid change (ATC isoleucine, ATT isoleucine; 
Ile1145Ile) (Ambudkar et al., 1999; Fung and Gottesman, 2009). Other polymorphisms 
that has previously been reported in high-frequencies include 1236C>T and 
2677G>T/A. The latter is a tri-allelic polymorphism at nucleotide 2677 in exon 21 of 
ABCB1. The non-synonymous polymorphism involves the transition of guanine (G) to 
thymine (T) or adenine (A) leading to one of two possible amino acid changes (GCT 
alanine, TCT serine, ACT threonine; Ala893Ser/Thr). It is found at residue 893 in a 
cytoplasmic loop of P-gp (Ambudkar et al., 1999; Fung and Gottesman, 2009). The 
occurrence of 2677G>T (Ala893Ser) and 2677G>A (Ala893Thr) is not similar with the 
first far more frequent than the latter (Fung and Gottesman, 2009).  
 
Another SNP, the 1236C>T polymorphism, is a silent polymorphism in exon 12 
of ABCB1. The SNP involves transition of cytosine (C) to thymine (T) at nucleotide 
1236. This does not result in an amino acid change (GGC glycine to GGT glycine; 
Gly412Gly) at residue 412 in a cytoplasmic loop (Ambudkar et al., 1999; Fung and 
Gottesman, 2009). Details on characteristic and position of ABCB1 polymorphisms are 
shown in Table 1.4. 
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Table 1.4 Characteristics and Positions of ABCB1 Polymorphisms  
Polymorphism  Characteristic mutation (s) Amino acid 
location  
Synonyms 
    
1236C>T 
(dbSNP 
rs1128503) 
At nucleotide 1236 in exon 
12, an cytosine (C)  is 
changed to a thymine (T) 
Gly412Gly g.87179601A>G 
g.87550285A>G 
g.167964T>C 
c.1236T>C 
p.Gly412= 
 
2677G>T/A 
(dbSNP 
rs2032582) 
Transition of guanine (G) to 
thymine (T) or adenine (A) 
at nucleotide 2677 in exon 
21 
Ala893Ser/Thr g.87160618A>C 
g.87160618A>T 
g.87531302A>C 
g.87531302A>T 
g.186947T>A 
g.186947T>G 
c.2677T>A 
c.2677T>G 
p.Ser893Ala 
p.Ser893Thr 
 
3435C>T 
(dbSNP 
rs1045642) 
At nucleotide 3435 in exon 
26, an cytosine (C)  is 
changed to a thymine (T) 
 
 
Ile1145Ile g.87138645A>G 
g.87509329A>G 
g.208920T>C 
c.3435T>C 
p.Ile1145= 
 
  
